Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Pharmaceuticals
Abbott, Galapagos Sign Arthritis Pact
by Rick Mullin
March 5, 2012
| A version of this story appeared in
Volume 90, Issue 10
Abbott Laboratories and Galapagos are joining to develop GLPG0634, an oral Janus kinase 1 inhibitor in Phase II development at Galapagos for the treatment of autoimmune diseases such as rheumatoid arthritis. Abbott will make an initial payment of $150 million to Galapagos. Upon successful completion of Phase II studies, Abbott will license the program for a one-time fee of $200 million and will take on full responsibility for Phase III trials. Additional milestone payments to Galapagos could amount to $1 billion.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter